Clinical Trial Update: Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial exploring molecularly targeted therapy with FOLFIRINOX in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma of the Extrahepatic Bile Duct
• Gallbladder Cancer

Drugs mentioned

• FORFIRINOX

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Cholangiocarcinoma of the Extrahepatic Bile Duct, Gallbladder Cancer | Phase 2 | Status: UNKNOWN